Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Gemcitabine, Erlotinib and Radiotherapy in Pancreatic Adenocarcinoma
NCT01389440Phase 2Completed
- Sponsor
- GEMCAD
- Start
- May 2011
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in pancreatic adenocarcinoma (PDAC), sponsored by GEMCAD. Started May 2011; status: completed.
02
Drugs
erlotinib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01389440.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01389440.